Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

407
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
407
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

315
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
315
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Bioequivalence: Overview01:16

Bioequivalence: Overview

921
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
921

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic assessment of diverse RNA modifications using nanopore direct RNA sequencing.

Nucleic acids research·2026
Same author

Online Determination of mRNA Poly(A) Tail Length and Content.

Analytical chemistry·2025
Same author

Unified and Versatile Multiplex Platform for Expedited Method Development and Comprehensive Characterization of Therapeutic Peptides.

Analytical chemistry·2024
Same author

Analytical and Functional Characterization of Plasmid DNA Topological Forms and Multimers.

Analytical chemistry·2024
Same author

Online Nucleotide Mapping of mRNAs.

Analytical chemistry·2024
Same author

Separation of Plasmid DNA Topological Forms, Messenger RNA, and Lipid Nanoparticle Aggregates Using an Ultrawide Pore Size Exclusion Chromatography Column.

Analytical chemistry·2023

Related Experiment Video

Updated: Jun 4, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Keeping up with a Quickly Diversifying Pharmaceutical Landscape.

Alexandre Goyon1

  • 1Synthetic Molecule Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.

ACS Measurement Science Au
|December 23, 2024
PubMed
Summary
This summary is machine-generated.

New therapeutic modalities like oligonucleotides, peptides, and gene therapies are emerging, presenting unique analytical challenges. Developing effective strategies is crucial for characterizing these complex drugs and ensuring their quality during development.

More Related Videos

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.3K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.6K

Related Experiment Videos

Last Updated: Jun 4, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.3K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.6K

Area of Science:

  • Pharmaceutical Science
  • Analytical Chemistry
  • Biotechnology

Background:

  • Traditional small molecules and antibodies dominated pharmaceuticals.
  • Emerging drug modalities address "undruggable" targets, driven by advances in biology and chemistry.
  • 2023 saw significant FDA approvals for oligonucleotide, peptide, and gene therapies (e.g., CRISPR-Cas9).

Purpose of the Study:

  • To discuss the analytical characterization challenges posed by novel drug modalities.
  • To share insights and strategies for overcoming these challenges in drug development.
  • To highlight the importance of robust analytical methods for new therapeutic approaches.

Main Methods:

  • Review of analytical challenges associated with diverse drug modalities (oligonucleotides, peptides, mRNA, DNA).
  • Discussion of impurity profiling, including closely related impurities and diastereomers from chemical modifications (e.g., phosphorothioates).
  • Consideration of quality attributes for mRNA and DNA, such as polyA tail length and capping efficiency.

Main Results:

  • Novel drug modalities exhibit diverse physicochemical properties, complicating analytical characterization.
  • Impurity formation during synthesis and shelf life requires sophisticated separation and profiling techniques.
  • Orthogonal methods are often necessary to resolve complex impurity profiles, including diastereomers.

Conclusions:

  • Analytical characterization of new drug modalities requires tailored strategies due to their complexity.
  • Addressing analytical challenges early in development is vital for data-driven decision-making.
  • Continued innovation in analytical methodologies is essential to support the growing field of novel therapeutics.